Drugs / PHST001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06840886 | Mar 2025 → Apr 2029 expected | breast cancer, central nervous system neoplasm, cholangiocarcinoma, endometrial cancer +3 | Pheast Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PHST001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06840886 ↗ |
| Action | Inhibit | “anti-CD24 macrophage checkpoint inhibitor” NCT06840886 ↗ |
| Route | Intravenous | “administered as IV infusions” NCT06840886 ↗ |